Pharmanovia to boost investment in nation
China DailyWith plenty of opportunities, China is expected to grow faster than other markets for United Kingdom-based global pharmaceutical company Pharmanovia, said a senior executive in an exclusive interview in Shanghai on Friday. Such continuous growth comes after China had already been the drugmaker's No 1 market globally since 2023, accounting for roughly 25 percent of the company's total sales, said James Burt, CEO of Pharmanovia, which was founded in 2013 and started business in China in 2018. Jin Chunlin, director of the Shanghai Municipal Health Development Research Center, said the aging process in China and the increasing demand for the treatment of major and rare diseases have also made the market more attractive for innovative drugs, which attracts domestic and foreign pharmaceutical firms alike. "China's new drug approval and public medical insurance policies have been inclined to support truly innovative pharmaceutical companies in recent years.